NBIX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
NBIX looks like a good buy right now for a beginner-focused, long-term investor with $50,000-$100,000 available. The stock has bullish momentum, supportive analyst upgrades, and a constructive options setup. While it is extended near short-term resistance, the overall setup is positive enough that I would rate it a buy rather than waiting for a perfect pullback, especially since the scenario indicates the investor is impatient and does not want to wait for an optimal entry.
NBIX is in an uptrend. MACD histogram is positive and expanding, showing strengthening momentum. The moving averages are bullish with SMA_5 above SMA_20 above SMA_200, which supports a sustained upward trend. RSI_6 at 76.64 suggests the stock is somewhat extended, but not enough to negate the trend. Price at 173.65 is near resistance at R1 172.49 and approaching R2 176.75, so the stock is strong but close to a short-term ceiling. Overall trend remains bullish.
Recent analyst action has been favorable, with multiple firms raising targets and keeping Buy/Outperform ratings. UBS raised its target to $208, Goldman Sachs reinstated coverage with a Buy and $213 target, and Oppenheimer/Piper Sandler remain constructive. The market is also favoring Neurocrine’s improving Ingrezza growth and Crenessity uptake, plus the Soleno acquisition adds Vykat XR and expands medium-term growth potential. There has been no negative news in the past week, which supports the bullish setup.
The stock is near near-term resistance and technically somewhat overbought. Some analysts still note concerns around Vykat timing and pipeline catalyst timing, and RBC mentioned the possibility that Crenessity uptake may face a near-term ceiling. The stock’s historical pattern data also suggests limited short-term downside drift in the next day and week before a stronger one-month move.
No recent quarter financial snapshot was provided because of a data error, so I cannot assess exact revenue or EPS figures. However, analyst commentary indicates the latest quarter was strong, with both Ingrezza and Crenessity sales exceeding expectations. The latest quarter season referenced in the analyst notes is Q1 2026, and the tone around financial growth is positive, with improving base business outlook and likely upward revisions ahead.
Analyst sentiment is clearly bullish overall. Several firms have raised price targets recently, with UBS at $208, Goldman Sachs at $213, Oppenheimer at $230, Piper Sandler at $207, and RBC at $183. The rating trend is mostly Buy/Outperform/Overweight, with only a few neutral views such as Morgan Stanley Equal Weight and Deutsche Bank Hold. Wall Street pros are generally positive on the stock because of stronger sales momentum, improving launch execution, and the Soleno/Vykat XR expansion, while the main caution is near-term execution timing and catalyst pacing.
